Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other EventsItem 8.01 Other Events.
On December 13, 2016, Trovagene, Inc. (the “Company”) issued a press release announcing that it will increase its focus on the global distribution of kits and systems to clinical research laboratories for the liquid biopsy oncology testing market. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
99.1 Press Release of Trovagene, Inc. dated December 13, 2016
About Trovagene, Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management. Trovagene, Inc. (NASDAQ:TROV) Recent Trading Information
Trovagene, Inc. (NASDAQ:TROV) closed its last trading session down -0.20 at 2.05 with 411,605 shares trading hands.